Search Results for keywords:"National Cancer Institute"

The National Cancer Institute has announced upcoming meetings focused on reviewing and evaluating grant applications, set to take place virtually on April 10-11, 2025. These meetings will be closed to the public to protect confidential information and personal privacy. They involve the National Cancer Institute Special Emphasis Panel, which aims to explore innovative technologies for cancer research. Interested parties can contact Jeffrey E. DeClue, the Scientific Review Officer, for further information.

The National Cancer Institute has announced a change in the date for a special meeting initially planned for February 24, 2025. The meeting will now take place on March 10, 2025, from 11 a.m. to 3 p.m. The format, location, and timing of the meeting will remain unchanged, and it will be conducted virtually. This meeting will be closed to the public.

The National Cancer Institute, part of the National Institutes of Health, has announced several upcoming meetings. These meetings, scheduled between January and March 2025, are intended to evaluate grant applications and contract proposals related to cancer research. The meetings will be closed to the public to protect confidential information and personal privacy. Each meeting will take place virtually, and further details, including contact information for scientific review officers, are provided for each session.

The National Cancer Institute has announced a change to the meeting date for the Special Emphasis Panel, initially scheduled for March 4, 2025. The meeting is now set for March 3, 2025, but the time and location remain the same, from 11:00 a.m. to 4:00 p.m. at the National Cancer Institute in Rockville, Maryland. The meeting will be conducted virtually and is closed to the public.

The National Cancer Institute is holding a closed meeting on April 10, 2025, to review and evaluate grant applications. This meeting is part of the NCI Transition Career Development Awards and Institutional Research and Education Training Grants. It will be held virtually from 9:00 a.m. to 7:00 p.m. The meeting will remain closed to the public to protect personal and confidential information involved in the discussions.

The National Cancer Institute has announced several upcoming closed meetings as required by the Federal Advisory Committee Act. These meetings will be virtual and are set to review grant applications and contract proposals, focusing on areas like cancer intervention, training, and research awards. The meetings are closed to the public to protect trade secrets and personal privacy. Each meeting will involve a committee of experts and will address different research and funding topics.

The National Cancer Institute is holding a closed meeting on March 9, 2021, to evaluate the personal qualifications, performance, and competence of individual investigators at the institute. This meeting, organized by the Board of Scientific Counselors, will take place virtually from 11:00 a.m. to 5:40 p.m. The meeting is not open to the public to protect the privacy of the individuals being evaluated. For more information, Brian E. Wojcik, Ph.D., can be contacted.

The National Cancer Institute is holding several meetings to discuss grant applications and contract proposals. These meetings will be closed to the public to protect confidential information, such as trade secrets and personal data. The meetings will take place in March and May 2021 at the National Cancer Institute in Rockville, Maryland, using telephone conference calls. Contact information for the scientific review officers in charge of each meeting is provided for those needing further details.

The National Cancer Institute has announced that there will be closed meetings where grant applications will be reviewed. These meetings are not open to the public to protect trade secrets, personal privacy, and commercial property. One meeting will happen on April 14, 2025, focusing on reviewing specific cancer research program projects. Another meeting is scheduled for April 16-17, 2025, to evaluate informatics technologies for cancer research. The meetings will take place virtually, and the responsible contacts are Leila B. Toulabi, Ph.D., and Susan Lynn Spence, Ph.D.

The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is considering giving Ziopharm Oncology, Inc. an exclusive patent license to develop and market certain cancer therapies. These therapies involve using a patient's own T cells that are engineered to target specific mutations in the P53 gene, which is commonly mutated in many cancers. The license will cover treatments made through a method known as transposon-mediated gene transfer but will not include those made using CRISPR technology. Interested parties have until February 9, 2021, to submit comments or license applications.